Rupee cost averaging, the cornerstone of Systematic Investment Plans (SIPs), may not remain effective in optimizing returns as accumulated amounts grow. The impact of regular SIP contributions on a larger portfolio tends to dilute, reducing the effectiveness of the strategy. Additionally, constantly relying on SIPs may lead to missed opportunities to make lump-sum investments during market downturns that could yield higher returns in the long run.
Vijay Kedia buys 9 lakh shares of SME stock Mahamaya Lifesciences in Rs 12.5 crore block deal
Ace investor Vijay Kedia acquired a significant stake in Mahamaya Lifesciences through a block deal. He purchased nearly 9 lakh shares at Rs 140 each.